|Day Low/High||37.59 / 37.87|
|52 Wk Low/High||37.20 / 45.58|
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing by GSK of a regulatory submission with the European Medicines Agency for once-daily, closed triple combination therapy...
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Relvar ® Ellipta ® (fluticasone furoate /...
Each dividend stock scores well for safety and has a historically high dividend yield.
These two pharmaceutical stocks offer great yields.
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing by GSK of a regulatory submission with the US Food and Drug Administration for the once-daily, closed triple combination...
A sale or spinoff of this business will likely get the attention of competitors that want to increase their over-the-counter product units.
Firms' 13F filings show how they've followed in the footsteps of the father of value investing.
This market is exploding in the U.S., presenting better investment opportunities than other types of therapies.
As we all know, the stock market and the economy abhor uncertainty.
Cramer shares his views on the rise of the stay-at-home consumer. Starbucks, Apple and Facebook are among the stocks discussed.
Jim Cramer ponders the preciousness of credibility.
Stocks in the health care sector seem to have no underpinnings whatsoever.
A partial victory for Brexit opposition and mixed corporate earnings drive markets in Europe.
Britain's largest pharmaceuticals company reports growth in its HIV medicines business as it submits a shingles vaccine for FDA approval.
The group's blood cancer drug Gleevec also holds up better than expected against generic competition.
Forward-looking purchasing managers' indices and earnings from beleaguered lender Deutsche Bank feature among the other release highlights.
For the week of October 24, investors await quarterly results from a slew of major companies, including Apple, along with the first estimate of third quarter GDP.
As the dust settles on Wednesday's contentious presidential debate, U.S. markets are actually teetering on the edge of breakout territory.
O'Shares Investment chairman and CNBC Shark Tank investor Kevin O'Leary says GlaxoSmithKline (GSK) has a huge advantage when selling to the U.S. market.
Britain's Brexit fortunes remain difficult to assess as markets offer mixed-signals on EU departure.
GlaxoSmithKline (GSK) appointed Brian McNamara CEO of its consumer healthcare division on Wednesday.
This pharmaceutical giant has struggled in recent years but is wisely repositioning itself as the world's largest manufacturer of vaccines.
Here is a look at two big pharma stalwarts to determine the better stock to buy for growth and income.
These stocks could be toxic to your portfolio in the month ahead.
Oil bounces back, German producer price data point to a continued low inflation outlook.
GlaxoSmithKline (GSK) named Emma Walmsley, the company's head of consumer healthcare, as CEO beginning next March.
Wells Fargo CEO John Stumpf will apologize Tuesday to the bank's customers in Senate testimony; U.S. stock futures are rising; GlaxoSmithKline names a new CEO.